Three active molecules have been identified from BN101E: BN102M, BN103M and BN104M
They have been shown to inhibit ERK1/2, JNK and NF-kB leading to suppression of TNF-α and IL-6 production
Proved to reduce disease severity in arthritic mice models by diminishing inflammatory cell infiltration and suppressing proinflammatory cytokine expressions in inflamed joints
The potential uses of the product include reduced disease severity and delayed disease progression
As a result of its research the company has an intellectual property portfolio of 45 granted patents